AWA
FATE icon

Artemis Wealth Advisors’s Fate Therapeutics FATE Stock Holding History

Artemis Wealth Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,000
Closed -$3.88M – 134
2022
Q1 		$3.88M Hold
100,000
– – 0.64% 8
2021
Q4 		$5.85M Hold
100,000
– – 0.73% 13
2021
Q3 		$5.93M Hold
100,000
– – 0.83% 9
2021
Q2 		$8.68M Hold
100,000
– – 1.24% 9
2021
Q1 		$8.24M Hold
100,000
– – 1.29% 10
2020
Q4 		$9.09M Buy
+100,000
New +$6.21M 1.45% 9

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Artemis Wealth Advisors's FATE Position: Q2 2022 in Review

Artemis Wealth Advisors sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 100,000 shares — an estimated $3.88M sold.

Artemis Wealth Advisors first reported a position in FATE in Q4 2020 and held it in 6 quarters. The position peaked at $9.09M in Q4 2020. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Artemis Wealth Advisors reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Artemis Wealth Advisors sold 100,000 Fate Therapeutics shares in Q2 2022, an estimated $3.88M.
  • Artemis Wealth Advisors first reported a position in Fate Therapeutics in Q4 2020 and held it in 6 quarters.
  • Artemis Wealth Advisors's Fate Therapeutics position peaked at $9.09M in Q4 2020.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Artemis Wealth Advisors's 13F filing for Q2 2022, filed 2 Aug 2022.